HBW Advisory Services LLC Boosts Stock Holdings in Pfizer Inc. (NYSE:PFE)

HBW Advisory Services LLC boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 39.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,284 shares of the biopharmaceutical company’s stock after buying an additional 2,893 shares during the period. HBW Advisory Services LLC’s holdings in Pfizer were worth $288,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of PFE. Argus Investors Counsel Inc. lifted its holdings in Pfizer by 17.2% in the fourth quarter. Argus Investors Counsel Inc. now owns 43,315 shares of the biopharmaceutical company’s stock valued at $1,247,000 after acquiring an additional 6,350 shares during the last quarter. International Assets Investment Management LLC lifted its stake in Pfizer by 2,150.2% during the fourth quarter. International Assets Investment Management LLC now owns 1,920,111 shares of the biopharmaceutical company’s stock worth $55,280,000 after purchasing an additional 1,834,781 shares during the last quarter. Prime Capital Investment Advisors LLC increased its stake in Pfizer by 39.5% in the fourth quarter. Prime Capital Investment Advisors LLC now owns 213,901 shares of the biopharmaceutical company’s stock valued at $6,158,000 after purchasing an additional 60,547 shares during the last quarter. Grimes & Company Inc. raised its holdings in Pfizer by 16.9% during the fourth quarter. Grimes & Company Inc. now owns 100,071 shares of the biopharmaceutical company’s stock worth $2,881,000 after purchasing an additional 14,488 shares in the last quarter. Finally, Stratos Wealth Partners LTD. lifted its position in shares of Pfizer by 3.6% during the 4th quarter. Stratos Wealth Partners LTD. now owns 224,179 shares of the biopharmaceutical company’s stock worth $6,454,000 after buying an additional 7,813 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Pfizer stock traded down $0.44 during trading hours on Tuesday, reaching $29.30. 28,998,532 shares of the stock were exchanged, compared to its average volume of 40,017,730. The stock has a market cap of $166.03 billion, a P/E ratio of -497.67, a P/E/G ratio of 1.07 and a beta of 0.69. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $37.19. The firm’s 50 day moving average is $28.75 and its 200 day moving average is $27.85.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. The company had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.31%. Pfizer’s quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.67 EPS. Analysts predict that Pfizer Inc. will post 2.68 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be paid a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, July 26th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.73%. Pfizer’s dividend payout ratio (DPR) is presently -2,800.00%.

Analyst Ratings Changes

Several brokerages have recently issued reports on PFE. Morgan Stanley upped their target price on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a report on Thursday, May 2nd. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Wednesday, July 31st. BMO Capital Markets restated an “outperform” rating and issued a $36.00 target price (up previously from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Barclays upped their target price on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Finally, Wells Fargo & Company upped their target price on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Eight research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, Pfizer currently has an average rating of “Hold” and an average target price of $34.58.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.